<p>NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis</p>

Abstract

Background: The oncogenicity of neural precursor cell-expressed developmentally down-regulated 9 (NEDD9) has been demonstrated in multiple cancer types. However, the prognostic value of NEDD9 in some solid cancers remains controversial. Thus, this meta-analysis was conducted to evaluate the relationship between NEDD9 expression survival rates in solid tumors. Method: Our meta-analysis included studies searched from various search engines with specific inclusion criteria and exclusion criteria. Combined HRs for overall survival (OS) and disease-free survival (DFS) or progression-free survival (PFS) or recurrence-free survival (RFS) or cancer-specific survival (CSS) were assessed using fixed-effects and random-effects models. The source of heterogeneity was identified by subgroup analysis. Additionally, publication bias was assessed using funnel plot and Egger’s regression asymmetry test. Result: Eighteen studies with a total of 2,476 patients were retrieved for analysis. Pooled HRs and 95% CIs were calculated. Both OS (HR=1.82; 95% CI: 1.43–2.31) and DFS/PFS/RFS/CSS (HR=2.54; 95% CI: 1.93–3.33) indicated that NEDD9 overexpression is associated with poor OS in cancer patients with solid tumors. Conclusion: NEDD9 overexpression might be a potential marker to predict prognosis in solid cancer patients.

Expression of NEDD9 and connexin-43 in neoplastic and stromal cells of gastric adenocarcinoma

“…In a subgroup analysis of patients with and without lymph node metastases, there were no significant differences in Cx43 and NEDD9 expression in patients without lymph node metastases , but patients with lymph node metastases showed higher expression of epithelial NEDD9 (Table 1, Figure 2). (14,(16)(17)(18)(19). Similar as in our study, expression of NEDD9 was found significantly increased in the tissue of pancreatic ductal adenocarcinoma compared to adjacent pancreatic tissue (18), but the same was not established in colorectal cancer (19).…”

NEDD9 overexpression: Prognostic and guidance value in acute myeloid leukaemia

“…8 It is not surprising that aberrant NEDD9 expression has been linked to the prognosis of human cancers. 8,20 In this study, we for the first time revealed that NEDD9 overexpression, identified from NEDD family, was associated with poor prognosis in AML. Notably, NEDD9 expression might act as a potential biomarker predicting prognosis and guiding treatment choice between chemotherapy and HSCT in AML.…”

“… 18 , 19 Overexpression of NEDD9 has now been strongly linked to poor prognosis in various types of cancers, as well as resistance to first‐line chemotherapeutics. 20 However, NEDD9 exhibits opposite effects regarding migratory capacity on myeloid cells as compared to epithelial or lymphoid cells, which block migration and dissemination of neoplastic cells of the myeloid lineage, while stimulating them in solid tumours or lymphoid neoplasias. NEDD9 −/− mice show an increased number of macrophages, and a simultaneous reduction of B lymphocytes in peripheral blood 21 and secondary lymphoid organs, yielding an almost complete loss of marginal zone B cells in the spleen.…”

<p>Anti-Proliferative and Apoptosis-Promoting Effect of microRNA-125b on Pancreatic Cancer by Targeting NEDD9 via PI3K/AKT Signaling</p>

“…23,24 NEDD9 has been implicated in the invasion ability of several tumors and has been speculated to be a candidate biomarker of invasiveness for lung cancer, breast cancer, melanoma, colon cancer and pancreatic cancer. 17,25,26 The function of NEDD9 related to cancer metastasis has focused on the FAK, Src and Akt signaling pathways. 27 The interactions of NEDD9 with FAK and Src led to the tyrosine phosphorylation of NEDD9 to create binding sites for effector proteins to facilitate cell migration.…”